chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient received first dose of pfizer vaccine on 4/4/21 and presented on 4/25/21 for his second dose as scheduled. At the second dose appointment he reported to the RN vaccinator that he believes the person to vaccinated him on the first dose administered it too high and he is having residual left shoulder pain that is slowly improving over the last three weeks. He has not been evaluated by his PCP but was recommended to do so.
Info has been received from a registered nurse concerning a 62-year-old female pt with dilated cardiomyopathy and no known allergies and no acute process who on 12/09/2002, also reported as 12/06/2002, was vaccinated IM in the left arm with a 1st dose of pneumococcal vaccine 23 polyvalent (Lot #644104/0873M). Concomitant therapy that day, also reported as 12/06/2002, included a 2nd dose of influenza virus vaccine (FLUSHIELD) (Lot #400-0011) given IM in the right arm. There were no chronic medications. On 12/10/2002, also reported as 12/07/2002, the pt developed a local reaction described as a "very painful and swollen arm". The pt was seen at an ER where her HCP saw her and recommended warm compresses. It was reported that the pt was scheduled to be seen 12/10/2002, but has not been heard back from since 12/07/2002. Follow up info received from a registered nurse indicated that on 12/10/2002, the pt developed redness and edema below the injection site. There was no acute distress. It was reported that the MD impression was a chemical reaction which was due to either irritation, questionable allergic reaction, or "TMT". Initially in the ER the pt was given diphenhydramine hydrochloride (BENADRYL) and ice. The pt was instructed to continue with cool compresses for 24 hours, then switch to warm compresses, and to elevate her arm. She was prescribed antihistamines and antiinflammatories prn, and instructed to follow up with her PCP. The report indicated that the pt recovered. No further info is expected.
Patient had dizziness and fall forward on the chair unconciously. Made the patient to lay on the back with legs on the chair until paramedicals arrived
Back ache set in about 12 hours after getting the vaccine.; minor joint pain; Woke up the following morning to body aches (lower back, right hip and knee,shoulder, headache) that lasted throughout the day.; Woke up the following morning to body aches (lower back, right hip and knee,shoulder, headache) that lasted throughout the day.; Woke up the following morning to body aches (lower back, right hip and knee,shoulder, headache) that lasted throughout the day.; Woke up the following morning to body aches (lower back, right hip and knee, shoulder, headache) that lasted throughout the day.; Headache that lasted throughout the day; Was generally tired; had a brieftemperature spike, but not highenough to be a fever.; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 03Apr2021 at 09:00 (at the age of 33-year-old) as a single dose for COVID-19 immunisation. The patient had not reported any other health issue. Concomitant medications included cetirizine hydrochloride (ZYRTEC) taken for an unknown indication from unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 03Apr2021 at 22:00, about 12 hours after getting the vaccine the patient reported back ache setting in. On 03Apr2021, the patient was generally tired and had a brief temperature spike, but not high enough to be a fever. On 04Apr2021, the following morning to body aches (lower back, right hip and knee, shoulder, headache) that lasted throughout the day. The patient was mostly back to normal the following morning and still had minor joint pain and occasional headaches. No therapeutic measures were taken for these reported events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events body aches (lower back, right hip and knee and shoulder) was resolved on 05Apr2021, that of tired and brief temperature spike, but not high enough to be a fever, was resolved on an unknown date in Apr2021, while that of minor joint pain/occasional headache was not resolved at the time of this report. The patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0169) via an unspecified route of administration in the left arm on 24Apr2021 at 10:00 (at the age of 33-year-old) as a single dose for COVID-19 immunisation.  No follow-up attempts are needed. No further information is expected.
face swelled up & skin peeled off inside nose- 1.5 weeks after 2nd moderna vaccine stomach hurt x1 week. Passed blood for a few days. Did have fever body aches. fatigue, hives all over body and head on 1st and 2nd covid
Noticed redness to site 72 hours after injection. Site today is sized as 40mmx32mm, warm to touch; site mildly sore.
The patient is having itching and swelling and a palpable lump  2 weeks post vaccination. The area is warm to the touch. The patient stated the lump continues to get larger and appeared shortly after the vaccine.  Referred to PCP.
No other issues or concerns noted; MMRII had a TE and had been administered; This spontaneous report was received from a medical assistant referring to a 12-month-old patient of unknown gender. Information about pertinent medical history, drug reaction/allergy and concomitant medication was not provided.  On an unknown date, measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) experienced temperature excursion with 47 Fahrenheit degrees for 6 minutes and 50 seconds.   On 04-APR-2022, the patient was vaccinated with the improperly stored measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) (rHA) (lot # U013036, expiration date 23-APR-2023; strength, dose, route of administration and anatomical location were not reported) for prophylaxis (product storage error). No other adverse event (AE) or product quality complaint (PQC) was reported.
Hives on arms stomach chest thighs neck. Heart racing and chest congestion. Friday still hives took Benadryl at night Saturday headache.
On the evening of the vaccine, I developed a fever, chills, body aches, and fatigue. These symptoms started about 5-6 hours after receiving the vaccine and subsided by the morning after.
None noted, called parent to reschedule 6 month WCC and mother told us baby had passed away. Did not give reason why.
Confirmed with customer that no other AE occurred; PROQU AD was administered after experiencing a temperature excursion; This spontaneous report was received from a nurse concerning, a patient of an unknown age and gender.   The patient's concurrent conditions, pertinent medical history and previous drugs reactions or allergies were not provided.  On 27-APR-2021 the patient was vaccinated with an improperly stored dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) recombinant human albumin (rHA), 1 dosage (lot # T005404, expiration date 12-AUG-2021 (reported as 24-MAR-2022), valid for company product) (strength, dose and route of administration were) for prophylaxis. No signs or symptoms were reported.  The doses of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) were exposed to a temperature excursion of 37.2 degrees Celsius(°C) during a time frame of 3 hours, which was detected by the data logger. There was no previous temperature excursion. No adverse effects were reported.
Systemic: Abdominal Pain-Medium, Systemic: Dizziness / Lightheadness-Medium, Systemic: Flushed / Sweating-Medium, Systemic: Nausea-Medium, Systemic: Vomiting-Medium
Information has been received from a nurse midwife concerning a 24 year old female with no pertinent medical history and no drug reactions/allergies who on 12-OCT-2007 was vaccinated with HPV rL1 6 11 16 18 VLP vaccine (yeast). Concomitant therapy included hormonal contraceptives (unspecified). On 14-OCT_2007 the patient experienced nausea, vomiting and fever on the Sunday and Monday after having received a dose of HPV rL1 6 11 16 18 VLP vaccine on Friday. The patient called the office on 16-OCT-2007 to report the symptoms and mentioned that she was feeling better. Additional information has been requested.
PT RECEIVED ONE DOSE OF PFIZER COVID VACCINE ON 4/18/21 AND CAME IN TO CHECK IN FOR COVID VACCINE. THIS LOCATION(0107) ONLY HAS MODERNA. PT RECEIVED A MODERNA SHOT 3 WEEKS AFTER HER FIRST PFIZER VACCINE. PT REPORTS THAT STATE WEBSITE HAS THIS LOCATION DISPENSING PFIZER VACCINE. NO ADVERSE REACTION WAS NOTED IN FIRST 15 MINUTES AFTER MODERNA ADMINISTRATION
Patient presented to emergency department 6 hours after vaccine administration with severe right arm pain, rated as 10/10, radiating from shoulder to elbow. Patient also reported chills but was afrebile upon presentation. Patient did not have redness or swelling around vaccine administration site. Emergency department diagnosed the pain as a shoulder sprain and prescribed tramadol 50 MG every 4 hours for pain.
sinus infection; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection) (Batch/Lot number: unknown) as dose 1, single for COVID-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: SINUSITIS (non-serious), outcome "unknown", described as "sinus infection". The event "sinus infection" was evaluated at the physician office visit. Therapeutic measures were taken as a result of sinusitis. Additional information: The patient's doctor prescribed amoxicillin for her sinus infection and the patient wanted to know if it will cause a problem/interaction if she will receive the second dose.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Information had been received from a pharmacist concerning a 66 year old female with an allergy to codeine who on 10/17/05 was vaccinated IM in the left arm with a 0.5ml dose of Pneumococcal 23v polysaccharide vaccine (lot 650327/0792P). It was reported that the pt came into the pharmacy yesterday, 10/19/05, and complained of a swollen left arm at the injection site. It was reported that the adverse event onset was within 72 hours. Unspecified medical attention was sought. The patient was treated with oral diphenhydramine hydrochloride Benadryl. At the time of the report the patient has not yet recovered. There was no product quality complaint involved. Additional information has been requested.
patient reported sever rash head and neck  patient did not report to provider until seen on 05/10/2019
Moderna COVID19 Vaccine.    I still have pain, tenderness, swelling in my left arm well over one month of taking the first dose.  The pain restricts me from stretching my arm out, over my head and behind my back. Practitioner recommended taking 600 mg of anti-inflammatory for 5 days.  Since pain still exists, he recommended I see an specialist.
MED ERROR.  COVID-19 VACCINE WAS GIVEN 1 WEEK EARLY
On 11/15/10 patient reports he noticed "swollen area" at injection site 11/12/10 evening. He reports there was slight discomfort at the site - no redness pt was afebrile. Area observed at clinic 11/16/10 swollen area 3" x 3 1/2". No redness. Referred to primary care provider.
10x5 cm area of swelling, redness, warmth, welt, took 4 days of pain, could not lie on that side, had cough, fatigue, slept for 24 hours, no fever.
1wk p/pt was vaxed pt's sibling devel clinical chickenpox;NP reported that the pt who was vaxed devel a case worse than sibling;pt vaxed 18AUG95 & devel clinical chickenpox w/>100 lesions 15SEP95 see VAERS ID 78795
Swelling; Left arm was warm to the touch; Redness has spread all over the left arm; Pain on the injection Site; Round red circle on the injection Site; Round red circle on the injection site got bigger; This spontaneous case was reported by a consumer and describes the occurrence of FEELING HOT (Left arm was warm to the touch), ERYTHEMA (Redness has spread all over the left arm), VACCINATION SITE PAIN (Pain on the injection Site), VACCINATION SITE ERYTHEMA (Round red circle on the injection Site) and VACCINATION SITE ERYTHEMA (Round red circle on the injection site got bigger) in an 84-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032K20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Cancer.   On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 18-Feb-2021, the patient experienced VACCINATION SITE PAIN (Pain on the injection Site), VACCINATION SITE ERYTHEMA (Round red circle on the injection Site) and VACCINATION SITE ERYTHEMA (Round red circle on the injection site got bigger). On 23-Feb-2021, the patient experienced FEELING HOT (Left arm was warm to the touch) and ERYTHEMA (Redness has spread all over the left arm). On an unknown date, the patient experienced SWELLING (Swelling). On 18-Feb-2021, VACCINATION SITE PAIN (Pain on the injection Site) outcome was unknown. At the time of the report, FEELING HOT (Left arm was warm to the touch), ERYTHEMA (Redness has spread all over the left arm), VACCINATION SITE ERYTHEMA (Round red circle on the injection Site), VACCINATION SITE ERYTHEMA (Round red circle on the injection site got bigger) and SWELLING (Swelling) outcome was unknown.            Most recent FOLLOW-UP information incorporated above includes: On 27-Apr-2021: additional info
pt recv vax 15AUG96 & 26SEP96  biaxin started for a poss sinusitis;p/dose 1 the day of vax pt had weak knees & exp discomfort;pt had not be running a fever;
swelling tongue; bottom lip was numb; This is a spontaneous report from a contactable consumer or other non hcp (patient) from a Pfizer-sponsored program Covax US Support. A female patient of an unspecified age received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number was not reported) via an unspecified route of administration on an unspecified date at dose 1, single for covid-19 immunisation. Medical history and concomitant medications were not reported. On an unspecified date the patient experienced swelling tongue, bottom lip was numb. Verbatim and event description: Reporter received first dose and experienced swelling tongue and bottom lip was numb for about 30 min Facility doesn't want to give her the second dose because of it, what should she do. Outcome of the events was unknown.  Information on the Lot/batch number has been requested.  Follow-up (12May2021): Follow-up attempts completed. No further information expected.
Hives all over the body / Full body hives; This spontaneous case was reported by an other health care professional and describes the occurrence of URTICARIA (Hives all over the body / Full body hives) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 30-Jan-2021, the patient experienced URTICARIA (Hives all over the body / Full body hives). At the time of the report, URTICARIA (Hives all over the body / Full body hives) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications were not provided. Treatment details were not provided.
Diverticulitis; This is a spontaneous report from a contactable consumer (patient). A female patient of an unspecified age received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number and expiration date were not reported), via an unspecified route of administration on 15Jan2021 at a single dose for COVID-19 immunization. The patient medical history and concomitant medications were not reported. It was reported that the patient took her first dose on 15Jan2021 and is scheduled for 05Feb2021. After the first shot, she got sick with diverticulitis and was put on antibiotics. The round of antibiotics will be done 02Feb2021 and on 03Feb2021 she will go through another test. She wanted to know if it is ok to get the second shot after finishing with the antibiotics. The outcome of the event was unknown.  Information on the lot/batch number has been requested.
Got 2nd Pfizer vaccine dose 10/5. Had nausea and vomiting on 10/6. Woke up  10/7 with diffuse sharp chest pain, pleuritic, non-radiating, non-exertional, unclear if positional. Symptoms waxed and waned into evening - coming and going 5 minutes at a time. After she received dose of Tylenol, pain dissipated completely. Came to ED, had observation admission, had cardiology consult and sent home 10/9 to f/u with cardiologist within 1 week. No further chest pain. Sent home on colchicine for at least 1-3 months, ibuprofen tid x7 days, outpt cardiac MRI, no vigorous activity 4-6 wks, f/u with cardiologist in office within 1 week.
whole body muscle aches; fever; chills; Headache; fatigue; This is a spontaneous report from a contactable consumer (patient). A 39-year-old female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number: EL3247), via an unspecified route of administration on 25Feb2021 10:15 (at 39-year-old) at single dose (Left arm) for COVID-19 immunization.  The patient medical history was not reported.  The patient's concomitant medications were not reported. The patient previously took avelox and experienced allergy, patient also previously took first dose of bnt162b2 (Lot number: EL3247) on 05Feb2021 10:15 at 39-year-old Left arm for COVID-19 immunization. Patient was not pregnant at the time of vaccination.  Facility where the most recent COVID-19 vaccine was administered was at the  clinic. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Patient did not receive any other medication within 2 weeks of vaccination. Prior to vaccination the patient was not diagnosed with COVID-19. The patient has not been tested for COVID-19 since the vaccination. The patient experienced Fever, chills, headache, whole body muscle aches, and fatigue on 26Feb2021 02:30. No treatment was given for events. The outcome of the events was recovered.
This spontaneous case was reported by a pharmacist and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (doses administered after excursion), PRODUCT TEMPERATURE EXCURSION ISSUE (vaccines which underwent a temperature excursion in the freezer were viable) and NO ADVERSE EVENT (No adverse event) in a 72-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7147B) for COVID-19 prophylaxis.     No Medical History information was reported.    At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (doses administered after excursion), PRODUCT TEMPERATURE EXCURSION ISSUE (vaccines which underwent a temperature excursion in the freezer were viable) and NO ADVERSE EVENT (No adverse event) outcome was unknown.      For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for POOR QUALITY PRODUCT ADMINISTERED (doses administered after excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (vaccines which underwent a temperature excursion in the freezer were viable).    No concomitant medications were provided.  Reporter reported that a temperature excursion that occurred several days ago in the Freezer. The excursion was found out in an audit and all the vaccines were viable.  No treatment medications were provided.
Pfizer 4/2/21, 4/23/21. Positive on 8/1/22
This spontaneous report was received from a medical assistant referring to a multiple unspecified patients of unknown age and gender. No information regarding the patients' medical history, concurrent conditions or concomitant therapies was provided. On an unknown date, the patients were vaccinated with improperly stored doses of ROTATEQ orally (strength, dose number, lot number and expiration date were not provided) for prophylaxis. No adverse events reported. No product quality complaint was involved. The vaccines were improperly stored with a temperature of excursion of: >46°F (fahrenheit degrees) but < 77°F (fahrenheit degrees) during 16 hours. There were no previous temperature excursion. This is one of two reports received from the same reporter. Additional information is not expected, since no consent to contact the reporter was provided.; Sender's Comments: US-009507513-1701USA002524:
Pt c/o itchy rash, blotchy skin the day following - from fingers to elbow x 2 days. Pt presents today with fist size lymphadenitis in (R) axillary that started after rash. Provider is unsure if this & vaccine are related.